Caristo’s novel technology transforms the diagnostic accuracy of routine coronary CT angiograms, a test used to identify patients with suspected heart disease. Using artificial intelligence, our proprietary technology provides unique insights about inflammation in the coronary arteries, the root cause of most heart attacks.
The validity of our novel biomarker, the Fat Attenuation Index (FAI), has recently been confirmed in a study by Kwiecinski et al, published in the Journal of the American College of Cardiology: Cardio...
American College of Cardiology Conference: At the American College of Cardiology Conference, an exciting abstract from Scientists at the US National Institute of Health (NIH) was presented showing a s...
University of Edinburgh: Congratulations to the SCOT-HEART investigators, who have been awarded a 2019 EuroMinnie Award for Scientific Paper of the Year. This is important recognition of the leading r...
European Society of Cardiology: Coronary computed tomography angiography (CTA) is an established and highly sensitive non-invasive technique to detect obstructive and non-obstructive coronary artery d...
UpToDate: We are pleased to report that Caristo’s new imaging biomarker, the Perivascular Fat Attenuation Index™ (FAI), has been featured in UpToDate’s latest chapter on Noninvasive Coronary Ima...
GDPR Statement.
For the purpose of contacting you, we will save your email address, phone number and the contents of your message. Should you wish to have these records removed please email: dpo@caristo.com
GDPR Statement.
For the purpose of contacting you, we will save your email address, phone number and the contents of your message. Should you wish to have these records removed please email: dpo@caristo.com